1-苄基-4-哌啶甲酸甲酯 | 10315-06-7

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-苄基-4-哌啶甲酸甲酯
• 中文别名: 1-苄基六氢异烟酸甲酯；N-苄基六氢异烟酸甲酯；N-苄基哌啶-4-甲酸甲酯；N-苄基-4-哌啶甲酸甲酯；1-苄基哌啶-4-甲酸甲酯
• 英文名称: methyl 1-benzylpiperidine-4-carboxylate
• 英文别名: 1-benzyl-4-piperidinecarboxylic acid methyl ester；methyl N-benzyl-4-piperidinecarboxylate
• CAS: 10315-06-7
• 化学式: C₁₄H₁₉NO₂
• mdl: MFCD09750949
• 分子量: 233.31
• InChiKey: MXOZSPRDEKPWCW-UHFFFAOYSA-N

物化性质

• 沸点：
  115 °C
• 密度：
  1.093±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H302,H319
• 储存条件：
  存于室温、干燥且密封的环境。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 1-benzylpiperidine-4-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 1-benzylpiperidine-4-carboxylate
CAS number: 10315-06-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H19NO2
Molecular weight: 233.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

1-苄基-4-哌啶甲醛作为中间体用于合成盐酸多奈哌齐，这一方法在研究和实际应用中被广泛采用。盐酸多奈哌齐是一种用于缓解阿尔茨海默病（AD）症状的长效药物。

反应信息

• 作为反应物：
  描述：

  1-苄基-4-哌啶甲酸甲酯 在 red-aluminum/morpholine complex 作用下， 以 甲苯 为溶剂， 反应 0.5h， 以96.5%的产率得到1-苄基-4-哌啶甲醛
  参考文献：
  名称：

  1-苄基-4-哌啶甲醛的制备方法

  摘要：

  本发明公开了一种1-苄基-4-哌啶甲醛的制备方法，包括如下步骤：在溶剂中，以1-苄基-4-哌啶甲酸甲酯或者1-苄基-4-哌啶甲酸乙酯与红铝配合物进行部分还原反应，然后从反应产物中收集1-苄基-4-哌啶甲醛。本发明的方法，以1-苄基-4-哌啶甲酸酯类为原料，以红铝配合物为还原剂，原料易于制备，操作简便，收率高，产品纯度好，适合于工业化生产。

  公开号：

  CN105693596A
• 作为产物：
  描述：

  4-哌啶甲酸 在 氯化亚砜 、 三乙胺 作用下， 以 甲醇 为溶剂， 反应 8.0h， 生成 1-苄基-4-哌啶甲酸甲酯
  参考文献：
  名称：

  N-苄基-4-哌啶甲醛的合成方法

  摘要：

  本发明属于药物合成技术领域，具体涉及一种N‑苄基‑4‑哌啶甲醛的合成方法。以4‑哌啶甲酸为原料，经酯化反应生成4‑哌啶甲酸甲酯盐酸盐，4‑哌啶甲酸甲酯盐酸盐经烷基化反应生成N‑苄基‑4‑哌啶甲酸甲酯，N‑苄基‑4‑哌啶甲酸甲酯水解得到N‑苄基‑4‑哌啶甲酸，N‑苄基‑4‑哌啶甲酸经酰化反应生成N‑苄基‑4‑哌啶甲酰胺，N‑苄基‑4‑哌啶甲酰胺脱水得到1‑苄基哌啶‑4‑腈，1‑苄基哌啶‑4‑腈经还原反应生成N‑苄基‑4‑哌啶甲醛。本发明方法反应条件温和，后处理简单，而且收率较高，在0℃就能以高收率得到N‑苄基‑4‑哌啶甲醛，不需要柱层析，且重复性高。

  公开号：

  CN111484444B

文献信息

• PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
  申请人：SHANGHAI BLUERAY BIOPHARMA CO., LTD.

  公开号：US20210053989A1

  公开（公告）日：2021-02-25

  Disclosed in the present disclosure are a pyrimidine-fused cyclic compound or a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer, solvate or isotope labeled compound thereof. Also provided in the present disclosure are a preparation method for the compound, a composition comprising the compound and a use of the compound for the preparation of a medicament for the prevention and/or treatment of a disease or condition associated with abnormal SHP2 activity.

  本公开涉及一种嘧啶融合的环状化合物或其药用可接受的盐、水合物、前药、立体异构体、溶剂合物或同位素标记化合物。本公开还提供了该化合物的制备方法、包含该化合物的组合物以及该化合物用于制备与异常SHP2活性相关的疾病或病况的药物的用途。
• Continuous-Flow Multistep Synthesis of Cinnarizine, Cyclizine, and a Buclizine Derivative from Bulk Alcohols
  作者：Svetlana Borukhova、Timothy Noël、Volker Hessel

  DOI：10.1002/cssc.201501367

  日期：2016.1

  Cinnarizine, cyclizine, buclizine, and meclizine belong to a family of antihistamines that resemble each other in terms of a 1‐diphenylmethylpiperazine moiety. We present the development of a four‐step continuous process to generate the final antihistamines from bulk alcohols as the starting compounds. HCl is used to synthesize the intermediate chlorides in a short reaction time and excellent yields

  肉桂利嗪，环利嗪，丁克利嗪和甲氯嗪属于抗组胺药家族，它们在1-二苯基甲基哌嗪部分上彼此相似。我们提出了一个四步连续过程的开发过程，该过程从大量的醇类作为起始化合物生成最终的抗组胺药。HCl用于在短的反应时间内合成中间氯化物，并具有优异的收率。该方法学提供了合成用于药物合成的中间体的绝佳方法。在线分离允许在以下步骤中收集纯净的产品并立即消费它们。肉桂利嗪，环齐嗪和丁克利嗪衍生物的总分离产率分别为82％，94％和87％。这四个步骤的总停留时间为90分钟，生产率为2 mmol h -1。
• Discriminating non-ylidic carbon-sulfur bond cleavages of sulfonium ylides for alkylation and arylation reactions
  作者：Jing Fang、Ting Li、Xiang Ma、Jiuchang Sun、Lei Cai、Qi Chen、Zhiwen Liao、Lingkui Meng、Jing Zeng、Qian Wan

  DOI：10.1016/j.cclet.2021.06.069

  日期：2022.1

  The disparate reaction pattern allowed the separate activation of non-ylidic S-alkyl and S-aryl bond. Under acidic conditions, sulfonium ylides serve as alkyl cation precursors which facilitate the alkylations. While under alkaline conditions, cleavage of non-ylidic S-aryl bond produces O-arylated compounds efficiently. The robustness of the protocols were established by the excellent compatibility of

  描述了一种在无过渡金属条件下参与烷基化和芳基化的锍叶立德。不同的反应模式允许单独激活非叶立基S-烷基和S-芳基键。在酸性条件下，锍叶立德用作促进烷基化的烷基阳离子前体。而在碱性条件下，非叶立基 S-芳基键的断裂可有效地产生O-芳基化化合物。协议的稳健性是由包括碳水化合物在内的各种底物的出色兼容性建立的。
• [EN] NOVEL INHIBITORS OF HISTONE DEACETYLASE 10<br/>[FR] NOUVEAUX INHIBITEURS DE L'HISTONE DÉSACÉTYLASE 10
  申请人：DEUTSCHES KREBSFORSCH

  公开号：WO2020193431A1

  公开（公告）日：2020-10-01

  The present invention relates to novel inhibitors of histone deacetylase 10 (HDAC10), novel pharmaceutical compositions comprising such inhibitors, and to novel methods of treating diseases, such as cancer, autoimmune disorders or neurodegeneration, using such novel inhibitors or methods of using such novel inhibitors in organ transplantation.

  本发明涉及新型组蛋白去乙酰化酶10（HDAC10）抑制剂，包括这种抑制剂的新型药物组合物，以及利用这种新型抑制剂治疗疾病（如癌症、自身免疫性疾病或神经退行性疾病）的新方法，或者利用这种新型抑制剂在器官移植中的使用方法。
• [EN] PYRAZOLOPYRIDINE DERIVATES<br/>[FR] DERIVES DE PYRAZOLOPYRIDINE
  申请人：URIACH Y COMPANIA S A J

  公开号：WO2004076450A1

  公开（公告）日：2004-09-10

  New compounds of formula (I) and the salts, solvates and prodrugs thereof, wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as p38 kinase inhibitors.

  公式（I）的新化合物及其盐、溶剂合物和前药，其中各种取代基的含义如描述中所披露的。这些化合物可用作p38激酶抑制剂。